Machine Learning for Pharmacokinetic/Pharmacodynamic Modeling

被引:8
|
作者
Tang, Albert [1 ]
机构
[1] Thomas Jefferson High Sch Sci & Technol, 6560 Braddock Rd, Alexandria, VA 22312 USA
关键词
Machine learning; Pharmacokinetic; pharmacodynamic modeling; Recurrent neural network;
D O I
10.1016/j.xphs.2023.01.010
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A variety of new recurrent neural networks (RNNs) including the ODE-LSTM, Phased LSTM, CTGRU and GRUD, were evaluated on modeling irregularly sampled PK/PD data with 6 or 12 time points/day and predicting PD data of unseen dosing regimens and dosing levels. The one-compartment absorption PK model and the Indirect PK/PD model I was used to simulate the PK/PD with inter-individual variabilities in volume of distribution and residual errors in PD measurement. The four RNNs were able to successfully model daily dose (QD) PK/PD and extrapolate to twice daily (BID) dose PD based on BID PK. The RNNs not only captured the additional fluctuations in the BID regimen but also the return phase to the baseline PD. However, extrapolating to unseen dose levels outside of the dose range for training proved to be challenging for all the RNNs tested. Only the GRUD demonstrated reasonable prediction results when extrapolating to unseen doses that were 3 or 10-fold outside the training doses. Overall, these new RNNs were able to overcome some limitations of previous RNNs evaluated and showed promise of integrating neural networks in PK/PD.(c) 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1460 / 1475
页数:16
相关论文
共 50 条
  • [21] How can machine learning and multiscale modeling benefit ocular drug development?
    Wang, Nannan
    Zhang, Yunsen
    Wang, Wei
    Ye, Zhuyifan
    Chen, Hongyu
    Hu, Guanghui
    Ouyang, Defang
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 196
  • [22] Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling
    Shen, Yuwei
    Kuti, Joseph L.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (01) : 13 - 25
  • [23] Population Pharmacokinetic/Pharmacodynamic Modeling of Guanfacine Effects on QTc and Heart Rate in Pediatric Patients
    William Knebel
    James Ermer
    Jaideep Purkayastha
    Patrick Martin
    Marc R. Gastonguay
    The AAPS Journal, 2014, 16 : 1237 - 1246
  • [24] Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
    Lei, Zhixin
    Liu, Qianying
    Xiong, Jincheng
    Yang, Bing
    Yang, Shuaike
    Zhu, Qianqian
    Li, Kun
    Zhang, Shishuo
    Cao, Jiyue
    He, Qigai
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [25] Population Pharmacokinetic-Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)
    Araujo, Ana Maria
    Machado, Humberto
    de Pinho, Paula Guedes
    Soares-da-Silva, Patricio
    Falcao, Amilcar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (05) : 617 - 628
  • [26] Extrapolation of Midazolam Disposition in Neonates Using Physiological-Based Pharmacokinetic/Pharmacodynamic Modeling
    Zhao, Tangping
    Lv, Zhanhui
    Zhou, Sufeng
    Wang, Lu
    Li, Tongtong
    Zhu, Jinying
    Shao, Feng
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025,
  • [27] Population Pharmacokinetic/Pharmacodynamic Modeling of Guanfacine Effects on QTc and Heart Rate in Pediatric Patients
    Knebel, William
    Ermer, James
    Purkayastha, Jaideep
    Martin, Patrick
    Gastonguay, Marc R.
    AAPS JOURNAL, 2014, 16 (06): : 1237 - 1246
  • [28] Machine learning for user modeling
    Webb, GI
    Pazzani, MJ
    Billsus, D
    USER MODELING AND USER-ADAPTED INTERACTION, 2001, 11 (1-2) : 19 - 29
  • [29] Machine Learning for User Modeling
    Geoffrey I. Webb
    Michael J. Pazzani
    Daniel Billsus
    User Modeling and User-Adapted Interaction, 2001, 11 : 19 - 29
  • [30] Statistical learning approach for predicting specific pharmacodynamic, pharmacokinetic, or toxicological properties of pharmaceutical agents
    Li, H
    Yap, CW
    Xue, Y
    Li, ZR
    Ung, CY
    Han, LY
    Chen, YZ
    DRUG DEVELOPMENT RESEARCH, 2005, 66 (04) : 245 - 259